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Addressing the targeting range of the
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sclerosis: A mixed methods psychometric study
Sophie Cleanthous, Sara Strzok, Farrah Pompilus, Stefan Cano, Patrick Marquis, Stanley Cohan,
Myla D Goldman, Kiren Kresa-Reahl , Jennifer Petrillo , Carmen Castrillo-Viguera,
Diego Cadavid and Shih-Yin Chen
Abstract
Background: ABILHAND, a manual ability patient-reported outcome instrument originally developed
for stroke patients, has been used in multiple sclerosis clinical trials; however, psychometric analyses
indicated the measure’s limited measurement range and precision in higher-functioning multiple scle-
rosis patients.
Objective: The purpose of this study was to identify candidate items to expand the measurement range
of the ABILHAND-56, thus improving its ability to detect differences in manual ability in higher-
functioning multiple sclerosis patients.
Methods: A step-wise mixed methods design strategy was used, comprising two waves of patient
interviews, a combination of qualitative (concept elicitation and cognitive debriefing) and quantitative
(Rasch measurement theory) analytic techniques, and consultation interviews with three clinical neu-
rologists specializing in multiple sclerosis.
Results: Original ABILHAND was well understood in this context of use. Eighty-two new manual
ability concepts were identified. Draft supplementary items were generated and refined with patient and
neurologist input. Rasch measurement theory psychometric analysis indicated supplementary items
improved targeting to higher-functioning multiple sclerosis patients and measurement precision. The
final pool of Early Multiple Sclerosis Manual Ability items comprises 20 items.
Conclusion: The synthesis of qualitative and quantitative methods used in this study improves the
ABILHAND content validity to more effectively identify manual ability changes in early multiple
sclerosis and potentially help determine treatment effect in higher-functioning patients in clinical trials.
Keywords: Manual ability, multiple sclerosis, ABILHAND, patient-reported outcomes, Rasch measure-
ment theory
Date received: 31 October 2017; Revised received 26 March 2018; accepted: 13 April 2018
Introduction
In addition to walking disability, cognitive prob-
lems, depression, and fatigue, manual disability is
a prominent problem for many people with multiple
sclerosis (MS)1–4 that affects the ability to perform
essential activities of daily living efficiently and
independently.1,5 Manual disability is common2–4,6
even in the early or mild stages of the disease, with
up to 60% of patients reporting symptoms in the
first year post-diagnosis.2 Therefore, change in
manual ability is an important aspect to monitor in
clinical practice for disease progression or therapeu-
tic effect. Traditionally, in clinical trials, manual
ability has been assessed using performance out-
come measures, such as the Nine-Hole Peg Test
(9HPT).7,8 These assessments, although practical
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for use in clinical settings, are not by themselves
informative about the daily life impact of MS (and
potential treatment benefit) on patients’ manual abil-
ity. Therefore, more robust patient-reported out-
comes (PROs) of manual ability are needed for
pivotal clinical trials and in the usual care setting
to assess treatment benefit from the patients’
perspective.
ABILHAND is a PRO instrument originally devel-
oped to assess manual disability in stroke9 but has
recently been used in clinical trials for MS.10–12 It is
essential to evaluate the extent to which any PRO
instrument provides valid measurement, and appro-
priately reflects the patient experience in any new
context of use.13,14 This may be achieved through
the discipline of psychometrics15 where three para-
digms exist: traditional psychometrics based on clas-
sical test theory (CTT),16 and modern psychometrics
including Rasch measurement theory (RMT)17,18
and item response theory (IRT). A previous CTT
study of ABILHAND-23 in MS suggested adequate
reliability and validity.19 However, subsequent RMT
evaluations of ABILHAND-2319,20 and
ABILHAND-5620 indicated limited measurement
range and precision (i.e., increased error associated
with measurement) in MS patients with Expanded
Disability Status Scale (EDSS) levels between 0–2,
which impact ABILHAND’s ability to detect differ-
ences in manual ability in higher-functioning MS
patients. Additional item fit analyses further sug-
gested that there is probably more than one clinical
concept related to manual ability underlying the
scale; these concepts are “fine motor” (dexterity)
and “power.”20
Given these limitations, the goal of the study pre-
sented here was to troubleshoot the ABILHAND-56
to increase its applicability to the broadest possible
population of patients with MS. As ABILHAND-56
is used on an ongoing basis in a specific drug devel-
opment program, addressing ABILHAND’s mea-
surement limitations in higher-functioning MS
patients is important to improve measurement
range, precision, and potential to detect treatment
effect, and subsequently confirm the item clarity
and relevance in MS. In this multi-phase, mixed
methods study, we aimed to build on previous
work by identifying additional candidate items to
build on the two clinical concepts underpinning the
ABILHAND-56, and thus to improve its ability to
detect differences in manual ability in higher-func-
tioning MS patients.
Materials and Methods
Study Design Overview
We used a step-wise mixed methods design strategy
comprising two waves of patient interviews, a com-
bination of qualitative and quantitative analytic tech-
niques, and consultation interviews with three clinical
neurologists specializing in MS (see Figure 1).
Mixed methods design is broadly defined as the com-
bination and comparison of multiple data sources,
data collection, analytical procedures, or research
methods.21 In psychometric research, mixed methods
specifically refers to the synthesis of qualitative and
quantitative methods to identify, define and opera-
tionalize PRO instruments as measures of a given
concept of interest in a specific context of use.14
Study Population and Recruitment Process
Institutional review board approval was obtained,
and written informed consent was provided by all
study participants. Early relapsing–remitting MS
(RRMS) patients were recruited through the study
sponsor’s patient services department and through
a social media site for MS patients. Patients were
eligible to participate if they were diagnosed with
RRMS within the last two years and had a Patient
Determined Disease Steps (PDDS)22 score of 0–1
(no to mild disability). The PDDS range was select-
ed to coincide with the EDSS 0–2 levels where pre-
vious research indicated limitations in the
ABILHAND’s measurement range and precision.
Patient Interviews
In Wave 1, concept elicitation interviews were used
to identify aspects of manual ability relevant to this
patient sample. This was to guide identification of
new items that could be used to supplement the
ABILHAND. We then asked patients to complete
the ABILHAND-56 to further assess its relevance
in early RRMS.
In Wave 2, we conducted cognitive debriefing inter-
views to establish relevance, clarity, and ease of com-
pletion of the draft supplementary items that were
generated in Wave 1. A “think aloud” process was
followed where patients were asked to complete the
items while thinking aloud and specifically noting any
queries, problems, or ambiguities of the question-
naire.23 All interviews were conducted over the tele-
phone; the ABILHAND-56 and supplementary items
were displayed on patients’ computer screens and item
responses captured via an online platform. Interviews
were audio-taped and transcribed verbatim. In
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addition, consultation interviews with three neurolo-
gists specializing in MS (SCohan, MDG, KKR) were
conducted at each of the two waves.
Materials
Based on the findings of our previous psychometric
analysis,20 an expanded four-level response scale,
very easy, easy, difficult, and impossible, was used
to improve the ABILHAND-56’s potential to cap-
ture manual disability in this early RRMS sample.9
Data Analysis
Qualitative analysis – concept elicitation.
Transcripts were analyzed thematically24 using
detailed line-by-line coding25 to examine, compare,
and develop treatment benefit conceptual domains
using ATLAS.ti software.26 Coding was targeted to
manual ability. Codes and quotations were induc-
tively categorized into overarching domains that
reflected their conceptual underpinning. Each code
was compared with the rest of the data to create
analytical domains and sub-domains. Saturation
was assessed by ordering interviews chronologically,
then grouping these into quantiles and comparing
concepts emerging by each sequential quantile to
assess whether saturation had been reached (i.e., no
new concepts emerged).
Qualitative analysis – cognitive debriefing. This
analysis aimed to identify any potential wording
ambiguities and assess relevance and acceptability
in relation to each question item, response scale
and set of instructions as well as identify additional
items that could expand the measurement of manual
disability in early RRMS.23
Item generation. Item generation followed item
construction principles,13,27–29 aiming to have an
adequate range of items to cover the conceptual
breadth within each of the upper limb mobility
sub-domains. Concepts chosen for item development
were activities that were applicable to the broadest
range of people with MS. Lay language was used in
item constructions, using as many of the patients’
own words as possible while aiming for brevity
and minimal semantic overlap.
Quantitative data analysis. A small-scale RMT
analysis was performed on data available for the
ABILHAND-56 at Wave 1 and ABILHAND-56 as
well as supplementary items at Wave 2 using
RUMM2030 analytical software.30 RMT analysis
compares observed data against the stringent criteria
of the Rasch model, broadly aiming to assess the
sample-to-scale targeting, the measurement continu-
um, and sample measurement.31,32 Considering the
Figure 1. Study overview. EMS: Early Multiple Sclerosis; MS: multiple sclerosis; RRMS: relapsing–remitting multi-
ple sclerosis.
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small sample size, which would not permit any confir-
matory conclusions to be made about the items’ mea-
surement properties, the focus of this quantitative
analysis was to improve to scale targeting. Targeting
refers to the match between the distribution of a con-
struct (e.g., manual disability) in the sample and the
range of the construct measured by a PRO instru-
ment.33,34 The better this match is, the greater the
potential for accurate evaluation of a PRO instrument
and accurate person measurement. Results were inter-
preted with reference to published criteria wherev-
er possible.32
Results
Study Sample
RRMS patients (n=88), with an RRMS diagnosis
<27 months, participated in Wave 1 interviews,
69.3% (n=61) of whom reported difficulties with
manual ability at screening (Table 1).
Wave 1 Qualitative Results
Concept elicitation. Eighty-two unique codes relat-
ed to manual disability were identified. Seventy-five
of these emerged as “upper limb” concepts in initial
coding; seven additional upper limb concepts were
identified in retrospective review of activity limita-
tion concepts. Inductive categorisation of these con-
cepts into higher order sub-domains and domains
replicated the two-level manual disability conceptual
structure suggested in earlier work.20 Early RRMS
patients indicated issues with upper limb mobility
related to dexterity that were categorised under the
“fine motor” sub-domain as well as issues related to
strength categorized under the “power” sub-domain
(Table 2). Consultation with the three neurologists
Table 1. Sample characteristics.
Patient demographic and
clinical characteristics
Wave 1 concept
elicitation sample
(n¼ 88)
Wave 1 RMT
analysis sample
(n¼ 29)
Wave 2 debriefing
and RMT sample
(n¼ 30)
PDSS score (n, %)
0 – normal 44 (50%) 18 (62.1%) 13 (43.3%)
1 – mild disability 44 (50%) 11 (37.9%) 17 (56.7%)
Age in years (meanSD) 40.0 (8.72) 38.51 (7.66) 35.07 (8.11)
Gender (n, %)
Male 23 (26.1%) 7 (24.1%) 7 (23.3%)
Female 65 (73.9%) 22 (75.9%) 23 (76.7%)
Race/ethnicity (n, %)
White 76 (86.4%) 26 (89.7%) 19 (63.3%)
Asian 1 (1.1%) 0 (0%) 1 (3.3%)
Black/African-American 5 (5.7%) 1 (3.4%) 5 (16.7%)
Hispanic/Latino 5 (5.7%) 1 (3.4%) 2 (6.7%)
Mixed race or “other” 1 (1.1%) 1 (3.4%) 3 (10.0%)
Education (n, %)
High school 11 (12.5%) 4 (13.8%) 2 (6.7%)
Some college/associate degree/
trade certification
28 (31.8%) 7 (24.1%) 12 (40%)
Bachelor’s degree 32 (36.4%) 11 (37.9%) 7 (23.3%)
Post-graduate degree 17 (19.3%) 7 (24.1%) 9 (30.0%)
Employment status (n, %)
Full time 57 (64.8%) 20 (68.9%) 22 (73.3%)
Part time 14 (15.9%) 1 (3.4%) 5 (16.7%)
Not employed 10 (11.4%) 5 (17.2%) 2 (6.7%)
Student 2 (2.2%) 1 (3.4%) 1 (3.3%)
Homemaker 5 (5.7%) 2 (6.9%) 0 (0.0%)
PDSS: Patient Determined Disease Steps; RMT: Rasch measurement theory; SD: standard deviation.
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specializing in MS was supportive of the two-
domain structure.
Saturation analysis indicated that the 88 interviews
produced a comprehensive set of concepts with rela-
tion to manual disability in higher-functioning
people with RRMS; 66 of 75 of the initially identi-
fied upper limb mobility concepts arose within the
first 30 interviews and the remaining nine concepts
either echoed concepts derived from earlier inter-
views, were not generalizable to the entire MS pop-
ulation, or already existed in the ABILHAND-56.
Item generation. Of the identified concepts, 40 of 82
were not covered by existing ABILHAND items; of
these, neurologist feedback suggested that 20 of
these 40 were more clinically relevant to MS
patients with less severe manual disability. This
led to the drafting of 23 items: 11 “fine motor”
and 12 “power” items. We identified these item
sets as Early Multiple Sclerosis Manual Ability –
Fine Motor and Early Multiple Sclerosis Manual
Ability – Power.
Cognitive debriefing, item reduction and
refinement. Findings from Wave 2 interviews sug-
gested that 20 of the 23 supplemental items were
well-understood and acceptable to patients.
However, three items appeared to overlap in
sub-domains. Patients interpreted “washing hair in
the shower” and “holding a full bag of groceries”
as relating to both lower limb and manual ability.
“Holding the steering wheel while driving for a long
time” was deemed unclear as patients associated this
item with multiple actions (including turning the
wheel and shifting gears). Subsequent consultation
with neurologists led to removal of the three items
not focused on manual ability and to wording revi-
sions of the remaining supplementary items. For
example, “inserting a cable into a USB port” was
changed to the more widely-applicable task of
“inserting a cell phone charging cable into a
cell phone.”
Final supplementary items for ABILHAND in early
MS. Findings from Wave 2 supported a final item
pool comprising 10 “fine motor” and 10 “power”
Early Multiple Sclerosis Manual Ability items
(Table 3).
Quantitative Results: RMT Psychometric Analysis
In line with previous findings,20 endorsement fre-
quencies indicated that none of the patients endorsed
the “impossible” response option for 49 of the 56
ABILHAND items in Wave 1 and 69 of the 79
ABILHAND plus supplemental items in Wave 2.
As this lack of endorsement of one of the four cat-
egories could artificially inflate the extent of
Table 2. Examples of patient descriptions under fine motor and power sub-domains.
Upper limb mobility
sub-domain Concept inductive code Example quote
Fine motor Brushing teeth Brushing one’s teeth – I would say very easy
right now, but when my hands are really
numb, it’s difficult. – BI-H-88
Fine motor Computer: mouse use But when I work with the computer, I can’t use
the mouse with my right hand. My wrist just
gets an attitude, and it just goes wherever it
wants. So, I have to use my left hand. –
BI-H-55
Fine motor Using keys There’s things like holding a key to put into a
keyhole can be challenging or even making
sure I have a good grip on my keys, so I don’t
drop them. – BI-W-28
Power Holding telephone Honestly, when I’m on my cell phone – you
know how you just lay on the couch with your
phone? I can’t (laughter) hold it up with my
left arm. I have to prop my arm up and look
at my phone. – BI-H-66
Power Lifting things I wasn’t able to lift the boxes down, put them
back up. BI-H-02
Cleanthous et al.
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Table 3. ABILHAND plus Early Multiple Sclerosis (MS) Manual Ability items, by theorized sub-scale.
ABILHAND 56-items
ABILHAND Fine Motor ABILHAND Power
AB1 Turning over the pages of a book AB8 Taking the metallic cap off a bottle
AB2 Pulling up the zipper of trousers AB11 Closing a door
AB3 Peeling onions AB12 Washing one’s face
AB4 Sharpening a pencil manually AB17 Opening a screw-topped jar
AB5 Using a spoon AB20 Tearing open a bag of chips
AB6 Using a screwdriver AB22 Combing one’s hair
AB7 Picking-up a can AB24 Hammering a nail
AB9 Filing one’s nails AB27 Making pancake batter
AB10 Grasping a coin on a table AB30 Washing one’s hands
AB13 Peeling potatoes with a knife AB31 Handling a stapler
AB14 Turning off a faucet AB32 Winding up a wrist watch
AB15 Buttoning up trousers AB35 Brushing one’s hair
AB16 Dialing on a keypad phone AB42 Cutting meat
AB18 Cutting one’s nails AB43 Eating a sandwich
AB19 Turning on a radio AB50 Shelling hazel nuts
AB21 Turning on the switch of a lamp AB51 Screwing a nut on
AB23 Unwrapping a chocolate bar AB54 Squeezing toothpaste on
a toothbrushAB25 Replacing a light bulb
AB26 Inserting a diskette into a drive
AB28 Spreading butter on bread
AB29 Counting paper money
AB33 Turning a key in a keyhole
AB34 Turning on a television set
AB36 Drawing
AB37 Ringing a door bell
AB38 Placing a glass on a table
AB39 Drinking a glass of water
AB40 Buttoning up a shirt
AB41 Threading a needle
AB44 Handling 4-color ballpoint pen
AB45 Blowing one’s nose
AB46 Wrapping up gifts
AB47 Fastening the zipper of a jacket
AB48 Fastening a snap
AB49 Writing a sentence
AB52 Opening mail
AB53 Typing
AB55 Taking a coin out of the pocket
AB56 Brushing one’s teeth
Early MS Manual Ability items
Fine Motor Power
FM01 Using a standard computer mouse P01 Holding up a book or tablet
while reading
FM02 Removing a credit card from slots/
pockets in a wallet
P02 Holding a phone up to one’s ear for
a long time
(continued)
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sub-optimal targeting for these analyses, the four-
level response scale was rescored into three levels,
merging the two higher categories (“very easy” –
“easy” – “difficult/impossible”) for this analysis.
Table 4 details the sample-to-scale targeting for the
different scale versions at Wave 1 and Wave 2.
Findings are presented in an interval 0–100 trans-
formed score, based on the interval logit metric
produced by RMT analysis. In alignment with the
sample’s PDSS scores, the sample mean was consis-
tently below the scale mean (<50), indicating that
these patients lie on the lower end of the manual
disability continuum. The supplementary items
both in their draft and final form shift the sample
measurement means closer to the scale mean for all
three different versions of the scale (36.65 to 38.87,
36.88 to 37.51 and 35.39 to 41.01 for the
Table 3. Continued
Early MS Manual Ability items
Fine Motor Power
FM03 Removing a single piece of paper
from a file folder
P03 Putting heavy items on a shelf
above head
FM04 Pushing buttons on a TV remote
control or similar device
P04 Taking a heavy item down from a
shelf above head
FM05 Texting on a cell/mobile phone P05 Pulling the cap off a pen
FM06 Opening the metallic tab of a
soda can
P06 Opening a safety cap on a medi-
cine bottle
FM07 Plugging an electrical plug into a
wall outlet that is easy to reach
P07 Lifting a full pot of water with one
handle off stove
FM08 Attaching a cell phone to a charg-
ing cable
P08 Filling a kettle with water
FM09 Inserting a key into a keyhole P09 Lifting a 20-lb weight one time
FM10 Accurately pouring liquids into a
measuring cup
P10 Blow drying one’s hair
Table 4. Overview of Rasch measurement theory (RMT) sample-to-scale targeting results.
ABILHAND scale version
Sample
measurement
rangea
Sample
measurement
mean (SD)a
Standard
error range
Sample
measurements %
beyond the
scale ceilingb
Wave 1 ABILHAND-56 1.35–48.74 40.59 (8.98) 1.68–9.67 3.70% (n¼1)
Wave 1 Fine Motor-39 3.09–50.49 40.39 (9.34) 2.12–9.94 7.49% (n¼2)
Wave 1 Power-17 10.05–49.90 40.50 (7.77) 1.98–10.11 7.49% (n¼2)
Wave 2 ABILHAND-56 9.66–47.45 36.65 (10.95) 1.80–5.46 20.00% (n¼6)
Wave 2 ABILHAND-56þ draft items 21.37–51.41 39.01 (7.75) 1.78–2.83 13.33% (n¼4)
Wave 2 ABILHAND-56þ final itemsc 21.10–51.84 38.87 (7.92) 1.79–2.89 13.33% (n¼4)
Wave 2 Fine motor-39 12.84–46.24 36.88 (10.64) 2.18–5.61 16.67% (n¼5)
Wave 2 Fine motor–39þ draft-items 17.92–47.93 37.86 (9.18) 2.24–3.95 13.33% (n¼4)
Wave 2 Fine motor–39þ final itemsc 16.47–48.42 37.51 (9.76) 2.25–4.18 16.67% (n¼5)
Wave 2 Power-17 2.68–51.27 35.39 (12.72) 3.70–11.61 23.33% (n¼7)
Wave 2 Power-17þ draft items 26.64–58.34 40.82 (6.85) 2.90–3.97 3.33% (n¼1)
Wave 2 Power-17þ final itemsc 27.78–59.07 41.01 (6.64) 2.96–3.94 0.00% (n¼0)
SD: standard deviation.
aWhere the scale item range is set to range from 0–100 and item mean always at 50; bpatients for whom the scale items
are too easy; cfinal items as available at Wave 2.
Cleanthous et al.
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ABILHAND, fine motor, and power scales
respectively).
The range of standard error (SE) associated with
measurement is also reduced by the added supple-
mentary items, indicating precision associated with
measurement is increased. The highest SE associated
with measurement is reduced from 5.46 to 2.89, 5.61
to 4.18 and 11.61 to 3.64 for the three respective
scales (Table 4). Finally, the percentage of people
at the ceiling (people for whom the scale items are
too easy) is reduced by the supplementary items for
the ABILHAND-56 and the Early MS Manual
Ability sub-scales. Figures 2–4 display the relative
improvements to sample-to-scale targeting
graphically.
Discussion
In this multi-phase, mixed-methods psychometric
study, we identified 20 additional candidate items
to help improve the ABILHAND-56’s ability to
detect differences in manual ability in higher-func-
tioning early RRMS patients. The robust develop-
ment process included patient and clinician
feedback as well as modern psychometric analysis.
Wave 1 in-depth qualitative research findings indi-
cated that the majority of existing ABILHAND-56
items were well-understood and appropriate to this
MS sample, confirming the ABILHANDs relevance
in this clinical population. In addition, we identified
a rich pool of relevant manual ability concepts align-
ing with the previously-identified two-level fine
motor and power manual ability conceptual frame-
work.20 Clinical neurologists helped ensure that item
development focused on the most clinically relevant
additional supplementary items to expand the
ABILHAND’s measurement range. Wave 2 patient
interviews ensured relevance, understanding, and
acceptability of the supplementary items, in addition
to providing evidence for revision and refinement.
The macro-level psychometric analysis of the addi-
tion of the new items, based on RMT, suggests
improved targeting in this higher-functioning
RRMS sample, with lower ceiling effects and greater
precision (the ability to discriminate different levels
of manual ability). The analysis also provided evi-
dence that an altered response scale to further
improve targeting for higher-functioning patients is
needed; this adaptation should therefore be consid-
ered for future MS studies using this scale.
A mixed method psychometric approach advances
our understanding of content validity and helps
ensure that a PRO instrument adequately reflects
the patient experience in a given context.13,14 This
process is vital to maximize clinical interpretability,
particularly when scores derived from PROs are
Figure 2. ABILHAND-56 sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original ABILHAND-56 items and (b) the improvements to the
match between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Manual Ability items.
Sample measurements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.
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used to make decisions about the state of disease and
treatment.35 Our study used a novel mixed methods
approach that demonstrates how we can efficiently
conduct psychometric research to empirically trou-
bleshoot legacy PRO instruments to ensure they
appropriately capture the targeted concept of interest
in a specific context of use.14
Traditionally, PRO instruments are developed via a
three-step approach moving through qualitative
concept elicitation and cognitive debriefing, to
quantitative field testing.36,37 However, we suggest
this standard linear methodology limits our ability to
efficiently construct items, elaborate upon response
options, identify anomalies, and troubleshoot overall
instrument design. Therefore, we advocate an inte-
grated, iterative process, prior to PRO instrument
field testing. Using this approach, we generated opti-
mal supplementary items for the ABILHAND in
MS, which could help improve the match between
manual ability in this population and subsequently
improve manual ability measurement and
Figure 3. Fine motor sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original Fine Motor 39 items and (b) the improvements to the
match between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Fine Motor items. Sample
measurements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.
Figure 4. Power sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original Power 17 items and (b) the improvements to the match
between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Power items. Sample meas-
urements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.
Cleanthous et al.
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interpretation in MS studies. It is important that the
supplemental items only be used in conjunction with
the ABILHAND items, as they do not measure the
full spectrum of MS manual ability on their own.
The outcome of this study has been the development of
a potential new tool, which could be used in clinical
practice and clinical trials to measure changes in
manual ability in MS from the patients’ perspective.
Attention to manual ability should be a central focus in
clinical management and development of new thera-
peutic/clinical interventions, including emerging can-
didate reparative therapies.38 In the current MS
research and treatment landscape, it is increasingly
clear that measures need to be targeted to include the
highly-functioning population, and need to be sensitive
to changes relevant to their functional status, particu-
larly in studies focusing on preserving physical ability
of newly diagnosed MS patients or reversing the
damage caused by the disease before irreversible
axonal loss takes place.19,20 Findings from this multi-
phase mixed methods study indicate that the Early MS
Manual Ability items expand manual ability measure-
ment to issues relevant to higher-functioning patients
and therefore have the potential to increase sensitivity
to detect subtle clinical change in higher-functioning
MS patients. The recent treatment effects observed
with natalizumab on the 9HPT components of the pri-
mary endpoint in patients with advanced non-relapsing
secondary progressive multiple sclerosis (SPMS) in
the ASCEND natalizumab trial highlight the impor-
tance of having robust clinical outcome assessments,
including PROs, to measure treatment effects on upper
extremity function.39
While our findings with Early MS Manual Ability
are encouraging, they should be interpreted with
consideration of the study’s limitations. The struc-
ture of the ABILHAND and Early MS Manual
Ability item stem (“How difficult are the following
activities”) is simple and function descriptions are
brief; patients reported they were able to complete
the items quickly, with few problems. However,
given that the enhanced conceptual coverage in
higher-functioning people with MS is achieved by
adding 20 items to the existing ABILHAND-56, it
will be worthwhile to explore the burden presented
by adding additional items in future studies. Given
that inclusion criteria were based on self-report
information and because of the small sample size
of the RMT analysis, additional analysis in a larger
clinically defined sample would help confirm the
validity and generalizability of these findings. The
scoring structure of the ABILHAND-56 and Early
MS Manual Ability items is empirically supported
by a psychometric analysis in one context and strict-
ly requires further psychometric testing. Finally, the
revised scoring structure improves but does not
resolve all the measurement issues related to the
original ABILHAND-56.
Through mixed methods psychometric research, we
generated 20 supplementary items to improve the
targeting on ABILHAND-56 in higher-functioning
MS patients. The qualitative and quantitative find-
ings support its use in measuring manual ability in
MS from the patients’ perspective. Further data from
a larger clinically defined sample is needed to con-
firm the new items’ measurement properties.
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